The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond

被引：0
|
作者：
Kazuomi Kario
机构：
[1] Jichi Medical University School of Medicine (JMU),Division of Cardiovascular Medicine, Department of Medicine
[2] JMU Center of Excellence,undefined
[3] Community Medicine Cardiovascular Research and Development (JCARD),undefined
来源：
Current Cardiology Reports | 2018年 / 20卷
关键词：
Sacubitril/valsartan; Angiotensin receptor neprilysin inhibitor (ARNI); Resistant hypertension; Cardiovascular continuum; Nocturnal hypertension; Systolic hypertension; Central blood pressure; Heart failure;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond
    Kario, Kazuomi
    CURRENT CARDIOLOGY REPORTS, 2018, 20 (01)
  • [2] Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Patients with Heart Failure
    Fala, Loretta
    AMERICAN HEALTH AND DRUG BENEFITS, 2015, 8 (06):
  • [3] First-in-Class Angiotensin Receptor Neprilysin Inhibitor in Heart Failure
    Vardeny, O.
    Tacheny, T.
    Solomon, S. D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (04) : 445 - 448
  • [4] LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure
    Martin P Lefkowitz
    BMC Pharmacology and Toxicology, 16 (Suppl 1)
  • [5] First-in-Class Composite Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Practice
    Barghash, M. H.
    Desai, A. S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 102 (02) : 265 - 268
  • [6] Entresto (Sacubitril/Valsartan): Angiotensin Receptor Neprilysin Inhibition for Treating Heart Failure
    Nicholas Phreaner
    Barry H. Greenberg
    Current Emergency and Hospital Medicine Reports, 2017, 5 (2) : 47 - 55
  • [7] THE ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR (ARNI), SACUBITRIL/VALSARTAN, IMPROVES LEFT VENTRICULAR MYOCARDIAL DEFORMATION IN HEART FAILURE WITH PRESERVED EJECTION FRACTION (PARAMOUNT TRIAL)
    Biering-Sorensen, Tor
    Shah, Amil
    Claggett, Brian
    Zile, Michael
    Pieske, Burkert
    Pieske-Kraigher, Elisabeth
    Voors, Adriaan
    Shi, Victor
    Lefkowitz, Martin
    Packer, Milton
    McMurray, John J. V.
    Solomon, Scott
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 2665 - 2665
  • [8] Cost Effectiveness of the First-in-Class ARNI (Sacubitril/Valsartan) for the Treatment of Essential Hypertension in a Chinese Setting
    Dong, Xinyue
    He, Xiaoning
    Wu, Jing
    PHARMACOECONOMICS, 2022, 40 (12) : 1187 - 1205
  • [9] Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor
    Dargad, Ramesh R.
    Prajapati, Mahesh R.
    Dargad, Rohit R.
    Parekh, Jai D.
    INDIAN HEART JOURNAL, 2018, 70 : S102 - S110
  • [10] Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan
    Clements, Richard T.
    Vang, Alexander
    Fernandez-Nicolas, Ana
    Kue, Nouaying R.
    Mancini, Thomas J.
    Morrison, Alan R.
    Mallem, Krishna
    McCullough, Danielle J.
    Choudhary, Gaurav
    CIRCULATION-HEART FAILURE, 2019, 12 (11)
12345